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Leukocyte extravasation is one of the essential and first steps during the initiation of inflammation. Therefore, a better
understanding of the keymolecules that regulate this processmay help to develop novel therapeutics for treatment of inflammation-
based diseases such as atherosclerosis or rheumatoid arthritis.The endothelial adhesionmolecules ICAM-1 andVCAM-1 are known
as the central mediators of leukocyte adhesion to and transmigration across the endothelium. Engagement of these molecules by
their leukocyte integrin receptors initiates the activation of several signaling pathways within both leukocytes and endothelium.
Several of such events have been described to occur during transendothelial migration of all leukocyte subsets, whereas other
mechanisms are known only for a single leukocyte subset. Here, we summarize current knowledge on regulatory mechanisms of
leukocyte extravasation from a leukocyte and endothelial point of view, respectively. Specifically, we will focus on highlighting
common and unique mechanisms that specific leukocyte subsets exploit to succeed in crossing endothelial monolayers.
1. Introduction
The inflammatory response is critical for fighting infections
and wound healing and is thus indispensable for survival [1,
2]. However, continuously active immune responses precede
chronic inflammatory disorders and other pathologies.Thus,
the immune response to injury and infection needs to be
tightly controlled. In order to specifically interfere with exces-
sive leukocyte transendothelial migration (TEM), a detailed
understanding of the regulation of this multistep process is
required. Butcher and Springer proposed in timeless reviews
a multistep model for the process of TEM [3, 4]. Currently,
this proposed model is still valid; however, over time some
additional steps have been added to the sequence of events
during TEM [2]. The inflammatory response starts with
secretion of proinflammatory mediators such as histamine
or cytokines that induce the opening of endothelial cell (EC)
contacts in postcapillary venules to allow for passage of blood
molecules, for example, complement factors. Inflammation
also involves surface expression of endothelial adhesion
molecules, actin remodeling, and activation of leukocyte
integrins that enable leukocyte adhesion onto the endothe-
lium within the vascular wall and subsequent diapedesis [5–
8]. The sequence of adhesive interactions of leukocytes with
EC is termed leukocyte extravasation cascade and involves
a series of adhesive interactions that allow first tethering,
rolling, and slow rolling, followed by firm adhesion, crawling,
and transmigratory cup formation on the apical endothelial
surface (Figure 1). Next is the actual TEM of leukocytes (also
termed diapedesis) that can occur by crossing either EC
contacts (paracellular) or the body of EC (transcellular). Both
ways exist and it is known that the strength of endothelial
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Figure 1: General scheme of the leukocyte extravasation cascade. The different steps of leukocyte interactions with endothelial cells during
adhesion and transmigration are depicted. The known adhesion receptor interactions are listed for each step with the leukocyte receptor
being named first. Unknown ligands are represented by question marks. During rolling, secondary rolling of leukocytes on already adherent
leukocytes can occur that involve interactions of leukocyte L-selectin with leukocyte PSGL1 (not depicted). All receptors are connected to
the actin cytoskeleton via actin-binding proteins to facilitate the extensive actin remodeling required for the morphological changes and
movement of both cell types involved (not depicted). For details, see text.
junctions controls route preference [9] but the exact underly-
ing mechanisms remain elusive. After crossing the endothe-
lium, leukocytes also have to cross the pericyte layer and
the basement membrane (BM) to reach the inflamed tissue
and contribute to clearance of infection and wound heal-
ing [10]. Different types of leukocytes are being recruited
to sites of inflammation including neutrophils, monocytes,
and lymphocytes. In response to an inflammatory stimulus,
neutrophils are generally among the first leukocytes to exit
the blood stream, and, after degranulation, they contribute
to a second wave of transmigration by mainly monocytes
[11]. The reverse case has also been observed, in which the
presence of monocytes and monocyte-derived neutrophil
chemoattractants were required for neutrophil recruitment
to sites of sterile inflammation [12]. Recruitment of all of
these leukocyte subsets is compulsory for a proper immune
response since all fulfill different functions once recruited
to the inflamed tissue [13]. All these leukocyte types follow
the sequential steps of the extravasation cascade in general,
but differences in responsiveness to certain chemokines and
in expression/activation of adhesion molecules to mediate
interactions with EC have been described [8, 14]. Several
mechanisms during the leukocyte extravasation cascade such
as certain receptor-ligand interactions or signaling pathways
have been confirmed as being exploited by all leukocyte
subsets. However, other mechanisms have so far only been
described for a single type of leukocyte. Whether these
mechanisms are indeed unique for a given leukocyte sub-
set or whether it has just not been studied yet in other
leukocyte subsets is an important question to be answered
in the future. A plethora of reviews have been published
that summarize several aspects of leukocyte recruitment but
in a generalized form that speaks only of “leukocytes.” In
this review, we summarize current knowledge on common
and unique mechanisms that different leukocyte types such
as neutrophils, monocytes, and lymphocytes exploit during
extravasation (Table 1). This includes signals induced within
each leukocyte subset as well as differential signals that each
leukocyte subset induces in EC to facilitate transmigration.
2. Mechanisms Exploited by Neutrophils to
Achieve Extravasation
Representing ∼40–60% of circulating leukocytes in the blood
of humans, released at a rate of ∼1-2 × 1011 cells per day
into the blood stream and with a lifespan of only 1–5
days [15], neutrophils are among the first leukocytes to be
recruited at sites of inflammation and/or injury. Migration
of these unique leukocytes through blood vessel walls is a
tightly regulated process for which some of the molecular
interactions with the different components of the vessel
wall (e.g., endothelium, pericyte sheath, and the venular
BM) have been relatively well described in the literature
[5, 14, 16]. There are now 5 major steps considered for the
recruitment of neutrophils, namely, (1) capture and rolling
along the luminal side of the endothelium, (2) firm adhesion
and crawling toward the site of TEM, (3) TEM (and its
variations), (4) subendothelial crawling along the pericytes
processes, and (5) exit into the extravascular space through
pericyte gaps and specific regions within the vascular BM.
Formany decades, it was assumed that chemokines and other
soluble chemoattractants were responsible for the specificity
of recruitment of leukocyte subsets due to a unique repertoire
of G-protein coupled receptors present on their surface
[17–19]. However, recent compelling in vivo evidences have
challenged this idea and demonstrated a role for many
adhesion molecules present on the EC surface specifically
instructing the neutrophil to extravasate [20–22].
2.1. Capture andRolling. Free flowing neutrophils are isolated
from the endothelium by a dense, 0.5 to 5𝜇m thick, network
of negatively charged proteoglycans, glycosaminoglycans,
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Table 1: Overview of some mechanisms that regulate extravasation of leukocyte subtypes in the order of events during the leukocyte
extravasation cascade.
TEM step Regulatory proteins Cell Function Reference
Tethering/rolling/slow
rolling
L-selectin, PSGL-1 EC/monos
L-selectin interacts with PNAd and
PSGL-1 with P- and E-selectin to
mediate proper rolling
[80]
P-selectin, Mac1 EC/monos Rolling and adhesion on ECM-boundplatelets under flow [84]
P-selectin, PSGL-1, and
CD44 EC/monos
Mediate rolling during monocyte
recruitment to lymphoid tissues during
inflammation
[79]
CD44 Neutrophils/T cell
CD44 interacts with E-selectin in
cooperation with PSGL-1 to mediate
rolling
[141]
TIM-1 T cell TIM-1 interacts with PSGL-1 to mediaterolling [140]
CD43 T cell
CD43 interacts with E-selectin in
cooperation with PSGL-1 to mediate
rolling
[142, 143]
P-selectin, PSGL1/PSGL-1
CD44, and L-selectin ECs/neutrophils
Mediate rolling during recruitment of
neutrophils in cremasteric postcapillary
venules
[21, 22]
PSGL-1, LFA-1/P-selectin,
and ICAM-2 Neutrophil/ECs Mediate sling formation and slow rolling [32, 37]
Arrest/adhesion
VLA-4 Monos PLC-, Ca-, and calmodulin-dependentarrest in response to chemokines [86]
VLA-4, GDF-15 Monos GDF-15 reduces VLA-4 activation andmonocyte adhesion [87]
LFA-1/ICAM-1 Neutrophils Mediate neutrophil arrest [42]
EphA2 EC Reduction of VCAM-1 expression andmonocyte adhesion [89]
DARC EC
CCL2 transport to the apical EC surface
to induce monocyte activation and
recruitment
[85]
SIRP𝛼/CD47 Monos/EC
Negatively regulates
𝛽2-integrin-mediated monocyte
adhesion and transmigration
[91]
CD47 T cell
Mediates integrin-dependent arrest on
VCAM-1 and ICAM-1 and T cell
recruitment in vivo
[145]
Kindlin 3 T cell Reinforces T cell adhesion [146]
CXCR4 Monos/B cell CXCL12-dependent adhesion anddiapedesis [159]
VCAM-1 B cell VCAM-mediated arrest without rolling [160]
Crawling
LFA-1, Mac1 Monos Locomotion in search for the nearestsuitable junction to start diapedesis [92]
LFA-1, Mac1 Monos
Crawling in unstimulated cremaster
venules LFA-1-dependent that becomes
Mac1-dependent after
TNF-𝛼-stimulation
[93]
LFA-1; CCL3/CXC3CL1 Monos Patrolling of resident monocytes andrecruitment into noninflamed tissues [72]
Mac1/ICAM-1 Neutrophils Control the luminal crawling ofneutrophils on endothelial ICAM-1 [42]
Mac1/ICAM-2 Neutrophils Control the directionality and speed ofcrawling of neutrophils on endothelium [45]
Cup formation
LFA-1/ICAM-1
VLA-4/VCAM-1
ALCAM-1
All
Clustering of these receptor-ligand pairs
around adhering leukocytes causes
GTPase activation, actin adaptor
molecule recruitment, actin remodeling,
and protrusion formation to engulf and
support the adherent leukocyte
[49, 50, 94–100]
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Table 1: Continued.
TEM step Regulatory proteins Cell Function Reference
TEM
JAM-A, JAM-L, JAM-C,
PECAM-1, DNAM-1,
CD155, and CD99
All
Serve as counterreceptors for
leukocyte-EC interactions during the
passage through interendothelial cell
contacts
[105, 108–112]
Mac1, NE/JAM-C Neutrophils/ECs
Control the directionality of neutrophil
transendothelial migration. Cleavage of
JAM-C induces aberrant
transendothelial migration
[57]
VAP-1
T cell Together with ICAM-1 and CLEVER-1specifically regulates T cell TEM [156, 157]
Monos
Support CX
3
CL1-dependent monocyte
transmigration across hepatic sinusoidal
EC
[161]
Neutrophils
Blocking enzymatic activity of VAP-1
reduces neutrophil diapedesis and
accumulation in lungs
[162, 163]
Occludin EC
Methamphetamine-induced Arp2/3
activation induces occludin
internalization and monocyte
transmigration
[113]
JAM-A MonosNeutrophils
Blocking JAM-A interaction with LFA-1
reduces recruitment of monocytes and
neutrophils into the brain after
ischemia/reperfusion injury
[107]
After TEM
CXCL1/ICAM-1
Mac1/LFA-1 Pericytes/neutrophils
Abluminal crawling along pericyte
processes [63]
VLA-3 VLA-6/collagen,
laminin
Neutrophils/venular
BM
Control the migration of neutrophils
through venular basement membrane
and exit through LERs
[10]
Interstitial motility
LFA-1
VLA-3 All
Interaction with abluminal ICAM-1
enables uropod extension while VLA-3
mediates movement of the leading edge
in the BM
[68]
ICAM-1 Pericytes
NG2+-pericytes secrete chemokines and
express ICAM-1 to attract/bind
transmigrated leukocytes
[114]
DDR1𝛼 Monos
Expressed after transmigration in vivo
to support migration within
collagen-rich ECMs
[118]
JAM-A Neutrophils Controls polarized interstitial migration [55]
RhoA Monos Active RhoA required for tail retractionto complete diapedesis [115]
and glycoproteins called the EC glycocalyx [23]. This struc-
ture acts as a formidable barrier for emigrating leukocytes
and exceeds the dimensions of cellular adhesion molecules
involved in neutrophil recruitment. Alterations of the EC
glycocalyx are therefore a prerequisite for the first steps of
neutrophil extravasation [24, 25]. Expression of positively
chargedmolecules such asMPOon the surface of neutrophils
[26] as well as shedding of the EC glycocalyx by heparinase
[27], release of neutrophil-derived reactive oxygen species
(ROS) [28], and matrix metalloproteinases (MMP) [29]
contribute to facilitation of neutrophil-EC contacts. Once
the EC glycocalyx is removed, neutrophils can reach the
endothelial surface via a specific class of 3 closely related
glycoproteins called the selectins and their glycoconjugate
ligands (P-selectin glycoprotein ligand-1 (PSGL-1), CD44,
and E-selectin ligand-1 (ESL-1)) [21, 30, 31]. L-selectin is con-
stitutively expressed on the surface of neutrophils, whereas
P- and E-selectins are more specific to EC. P-selectin is
constitutively stored in distinct EC granules called Weibel-
Palade bodies that are rapidly mobilized to the EC surface
where P-selectin gets homogeneously distributed on the
cells. By contrast, E-selectin is synthetized de novo during
activation and concentrated mainly at EC junctions. Inter-
estingly, a new study from Zuchtriegel and colleagues [22]
demonstrated that neutrophils mainly use P-/L-selectin and
PSGL-1/CD44 but not E-selectin to tether and roll along
the endothelium in vivo. When blocked, these interactions
affected not only the flux of rolling neutrophils but also their
subsequent firm adhesion, crawling, and TEM. By contrast,
inflammatory monocytes additionally need to interact with
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E-selectin for proper transmigration across the vessel wall,
thus highlighting a new singular difference in the molecular
interactions between different subsets of leukocytes and EC
during this first stage of transmigration.
Despite the weak and transient nature of the molecular
interactions between selectins and their ligands, neutrophils
roll even under high shear stress within blood vessels.
Sundd and colleagues have recently made some interesting
observations on how these neutrophils maintain contact with
EC during rolling [32]. During the initial contacts with
EC through selectins/selectin ligands, the structure of the
neutrophil cell membrane is modified by reorganization of
both cytoskeleton and surface adhesion molecules leading to
the formation of an extended protrusion called sling [33].
This structure is formed from a membrane tether at the
back of the rolling neutrophil like an anchor before it is
wrapped around the rolling leukocyte and swings to the
front of the cell to recontact the EC. Such slings contained
heterogeneous patches of PSGL-1 conferring intermittent
adhesive structures to the EC surface but are also rich in
the 𝛽2-integrin lymphocyte function-associated antigen-1
(LFA-1). Furthermore, the binding of PSGL-1 to P-/L-selectin
during the rolling step leads to conformational changes in the
neutrophil 𝛽2-integrin LFA-1 through outside-in signalling
[34–36]. This response allows for binding of LFA-1 to its lig-
ands on EC supporting slow rolling and eventually transition
to firm adhesion of the neutrophil [37].
2.2. Firm Adhesion and Crawling. Strengthening of neutro-
phils-EC interactions occurs mainly through the bind-
ing of the leukocyte 𝛽2-integrins LFA-1 and macrophage-
antigen-1 (Mac1) to their cognate receptor intercellular
adhesion molecule-1 (ICAM-1) expressed on activated EC
[38]. These interactions enable the neutrophils to firmly
adhere to the surface of the endothelium. In parallel to 𝛽2-
integrins/ICAM-1 adhesive complexes, the neutrophil 𝛽1-
integrin very late antigen-4 (VLA-4) and its EC binding
partner vascular cell adhesion molecule-1 (VCAM-1) can
contribute to the arrest of leukocytes in specific inflammatory
conditions in humans [39]. This strengthened adhesion is
completed by the sensing of chemotactic molecules such
as chemokines (e.g., CXCL1/2), lipid mediators (e.g., LTB4,
PAF), and complement proteins (e.g., C5a) by G-protein-
coupled receptors (GPCRs) on the surface of the neutrophils
that further signal through the cytoskeleton to induce full
activation of the integrins and firm adhesion [37]. Following
this firm adhesion, neutrophils crawl perpendicular to or
even against the flow of the bloodstream, toward chemo-
tactic [40] (e.g., chemokines) or haptotactic (e.g., ICAM-2)
gradients. The mechanism of this luminal crawling is strictly
ICAM-1/Mac1-dependent [41, 42] as blockade of these two
molecules in vivo resulted in neutrophils failing to both
crawl and migrate through EC junctions without affecting
neutrophil adhesion. It has been suggested that the tran-
sition between LFA-1-dependent firm adhesion and Mac1-
dependent crawling of neutrophils occurs via inside-out
signalling through LFA-1 and the activation of the guanine
exchange factor Vav-1 [43] that consequently activates Mac1
[44]. Recently, another member of the CAM family, ICAM-
2, has been shown to play a role in neutrophil crawling
dynamics toward EC junctions prior to TEM [45]. In mice
exhibiting genetic deletion of this molecule as well as in
WT animals treated with a blocking antibody against ICAM-
2, neutrophils exhibited an increase in crawling duration
and reduced crawling speed, leading to neutrophils lingering
longer along the luminal surface of EC and delaying their
migration through endothelial junctions.
2.3. TEM and Its Variations. TEM is the most rapid response
of the migration cascade of neutrophils, lasting 5–10min
depending on the inflammatory scenario. Several molecular
interactions betweenneutrophils andEChave been described
for this step in the literature [5, 14, 16]. The penetration
of EC by neutrophils occurs via two routes: through EC-
EC intercellular junctions (i.e., paracellular migration) or
through the body of the EC (i.e., transcellular migration).
Recent in vivo evidence showed the predominance of the
paracellular route (90% of transmigration events) over the
transcellular migration [46]. Genetically modified mice in
which the adherens junctions and more particular the VE-
cadherin-catenin/VE-PTP complex are stabilized showed
that the blood vessel wall became impermeable to macro-
molecules and neutrophil infiltration [47, 48]. By contrast,
mice deficient for the actin-binding protein cortactin showed
reduced clustering of ICAM-1 around adherent neutrophils
due to defective activation of the GTPase RhoG in EC
leading to strongly reduced adhesion and transmigration
[49, 50]. Numerous adhesion molecules enriched at EC-
EC junctions such as PECAM-1, JAM family members,
ICAM-2, CD99, ESAM, and CD99L2 are involved in the
process of neutrophil TEM.Thesemolecules are also detected
in subcellular structures called the lateral border recycling
compartment (LBRC) that play a key role in neutrophil TEM
[51, 52]. In basal conditions, these adhesion molecules con-
tribute to the maintenance of EC junctions; however, during
inflammation they engage with their counter-receptors on
neutrophils (e.g., 𝛽2-integrins LFA1 and Mac1 and through
homophilic interactions of PECAM-1, JAM-A, or CD99 that
are also expressed on leukocytes) to allow for crossing of the
junctions in a sequential manner [16, 53, 54]. The binding
of adhesion molecules between neutrophils and EC can
also mediate polarization signals in the neutrophils allowing
them to correctly migrate from the luminal to abluminal
sides of the EC. This is particularly true for JAM-A [55]
and JAM-C [56]. Two recent publications demonstrated in
vivo the presence of abnormal transendothelial migratory
events [46, 57] characterized by the neutrophil partially
migrating through the junction with oscillatory movements
in the junction (i.e., hesitant migration) or even returning
back to the circulation in an abluminal-to-luminal direction
(reverse migration) following ischemia-reperfusion injury
or leukotriene B4- (LTB4-) induced inflammation. This
abnormal transmigration can represent up to 20% of total
TEM events. This response could be reproduced or even
enhanced in other inflammatory conditions in the absence or
by blockade of JAM-C [46]. Abnormal transmigration indeed
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involves the removal of JAM-C from the junction via cleavage
by neutrophil elastase [57] following its translocation from
azurophilic granules to the surface of the leukocyte in a com-
plex with the integrin Mac1 upon direct stimulation of the
neutrophil by LTB4 [58]. Genetic deletion or pharmacologi-
cal inhibition ofNE could significantly restore the presence of
JAM-C at junctions and reduce the abnormal transmigration
events. On the other hand, exogenous injection of NE in
inflammatory models not known for exhibiting abnormal
TEM of neutrophils increased the number of these events.
This specific abnormal TEM response was associatedwith the
presence of soluble JAM-C in the serum and an increase in
secondary organ damage, two key features regularly observed
in patients with trauma or ischemia-reperfusion injury.
2.4. Abluminal Crawling. Earlier observations of migration
events showed that, after TEM, the vessel wall was thick-
ening and neutrophils could only be detected in the tissue
more than 20–40min after TEM had occurred. For many
decades, nothing was known about what was happening to
the neutrophil during this period of time. Once migrated
through the EC, the abluminal neutrophil faces the second
cellular component, that is, the pericytes, and its tight matrix,
the venular basement membrane (BM), in which they are
embedded [59]. Many of the studies of transmigration events
have neglected these two components of blood vessel walls
due to the difficulty to reproduce the complete structure in
vitro or to visualize it in vivo. However, recent developments
of new advanced microscopy techniques and the generation
of genetically fluorescent animals have shed new lights on the
role of pericytes in the recruitment of neutrophils in vivo.
Pericytes express adhesion molecules and chemokines such
as ICAM-1, VCAM-1, and CXCL1 upon inflammation both in
vivo and in vitro [60–63]. This response was correlated with
the observations that, after TEM, neutrophils were found
crawling along pericyte processes away from their site of TEM
in an ICAM-1/Mac1- (and to a lesser extent LFA-1) dependent
manner before fully breaching the venular wall [63]. Blocking
those molecular interactions with blocking antibodies could
suppress both neutrophil abluminal motility and their entry
into the interstitial space.
2.5. Exit from the Vessel Wall. Following abluminal crawling,
neutrophils exit the vessel wall through specific enlarged
gaps between adjacent pericytes. The role of pericyte gap
enlargement is still unclear, but, interestingly, less than 10%
of the gaps were used by migrating neutrophils and most of
the time hot spots of transmigration could be observed where
more than 2-3 neutrophils exited via the same pericyte gaps.
It has been suggested that potential enrichment in adhesion
molecules and chemokines around specific pericyte gaps [63]
as well as the release/generation of chemoattractants by the
leading neutrophils from their granules [11] and/or from the
cleavage of BM proteins into chemotactic fragments [64]
could pave the way for subsequent neutrophils.
The venular BM (generated by both the EC and the
pericytes) is the final interactive matrix (but also barrier)
for emigrating neutrophils. This structure is composed of
tight networks of matrix proteins such as collagen type IV
and laminins [65]. Interestingly, blocking the interactions
between leukocyte integrins VLA-3 andVLA-6 (receptors for
collagen and laminin, resp.) and the venular BM using block-
ing antibodies could inhibit the migration of neutrophils
through this layer [66–68]. Another unique characteristic of
neutrophil interaction with the venular BM is the discovery
of low expression regions (LERs) within the BM that are
preferred sites for neutrophil migration [10, 59]. These sites
contain low quantities of matrix proteins, are associated with
gaps between adjacent pericytes, and are being used and
enlarged during neutrophil, but not monocyte, migration
[69]. In fact, it will take another 10 to 20 minutes more for
the neutrophils to migrate through pericyte gaps and LERs
as observed in vivo, with many oscillatory movements by
the neutrophils [63]. However, the duration of LER/pericyte
gap penetration and oscillatory movements are reduced for
the subsequent neutrophils following the same hot spot of
migration. Though the mechanism of the remodelling of
such permissive sites in the BM of venular walls is not fully
understood, it has been suggested that proteolytic cleavage
by neutrophil enzymes [10, 59] and/or reversible disassembly
of collagen fibres [65] could be involved in this process, thus
allowing the neutrophil to finally access the interstitial space.
3. Mechanisms Exploited by Monocytes to
Achieve TEM
3.1. Monocyte Populations. Monocytes are heterogeneous
cells that circulate in the blood in distinguishable popu-
lations termed resident (or patrolling) and inflammatory
monocytes according to the expression profile of certain
chemokine receptors and adhesionmolecules [70–72].While
resident monocytes are associated with immune surveillance
and wound healing, inflammatory monocytes are connected
to induction and maintenance of inflammatory immune
responses [73]. On the other hand, monocytes give rise to
dendritic cells and macrophages to promote inflammatory
responses [74, 75]. Monocytes are actively being recruited
from the bone marrow via the blood stream to inflamed
tissues in a largely CC-chemokine receptor 2/CC-ligand-2-
(CCR2/CCL2) dependent fashion. Very recently, an elegant
intravital imaging study reported a phenotypic conversion
of monocyte subsets at sites of sterile liver injury [76]. First,
inflammatory monocytes were rapidly recruited and stayed
around the injured site for about 48 h before a conversion to
a resident monocyte phenotype and entry into the injured
area occurred to induce wound healing. This previously
unrecognized monocyte plasticity highlights the importance
of monocytes for resolution of inflammations. Furthermore,
a targeted silencing approach using nanoparticles contain-
ing CCR2-specific siRNA has been described in mice that
prevented accumulation of inflammatory monocytes at sites
of inflammation and ameliorated various pathological con-
ditions in which inflammatory monocytes have been impli-
cated [77]. This is a promising approach to specifically target
inflammatory monocytes without affecting other immune
cells during inflammation; however, it remains to be proven
whether such an approach is applicable to humans.
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3.2. Rolling and Slow Rolling. TEM of monocytes occurs
according to the paradigm of the leukocyte extravasation
cascade as described above [78]. In addition to the well-
established role of PSGL-1 in all leukocyte rolling, mono-
cyte rolling during recruitment to lymphoid tissues also
depended on L-selectin and CD44 [79]. In the infected
skin, proper monocyte rolling and subsequent recruitment
depended on monocyte PSGL-1 interaction with endothelial
E- and P-selectin, whereas monocyte L-selectin interacted
with endothelial peripheral node addressin (PNAd) [80]. L-
selectin shedding is required at later stages of transmigration
to ensure a regulated and polarized conclusion of transmi-
gration [81]. On EC expressing high amounts of VCAM-
1, for example, in atherosclerotic lesions, monocyte rolling
and transition to slow rolling and arrest strongly depended
on the 𝛽1-integrin VLA-4 [82, 83]. However, on ECM-
boundplatelets,monocyte rolling rather depended on the𝛽2-
integrin Mac1 and P-selectin [84].
3.3. FirmAdhesion. Once slowed down, leukocytes recognize
chemokines presented on the endothelium that lead to
GPCR-mediated inside-out signaling, full integrin activation,
and the subsequent arrest of leukocytes. The endothelial
Duffy antigen receptor for chemokines (DARC) has recently
been reported to transport CCL2 across the endothelium
to the apical side where it contributed to proper monocyte
activation and recruitment [85]. In monocytes, full VLA-
4 activation after GPCR stimulation depended on a sig-
naling axis including phospholipase C (PLC), inositol-1,4,5-
triphosphate (IP3), Ca2+-flux, and calmodulin but not on
PI3K [86], which is in contrast to VLA-4 activation in neu-
trophils. Although the adhesion cascade has been best studied
in neutrophils (reviewed in [8]), a common denominator
regulating the transition from rolling via slow rolling to
arrest in all leukocytes is the activation of PLC. However,
depending on the stimulus, the primary integrin inducing
firm adhesion/arrest varies among leukocyte subsets. In the
case of monocytes, it seems to be VLA-4. Recently, growth
differentiation factor-15 (GDF-15) has been identified as an
endogenous inhibitor of VLA-4 activation that prevented
monocyte binding to VCAM-1 and could thus serve as a local
inhibitor of inflammation [87]. VCAM-1 expression and thus
monocyte adhesion are increased by the endothelial receptor
protein tyrosine kinase EphA2 [88, 89]. Other examples of
endogenous monocyte integrin inhibitory molecules are the
endothelial matrix protein developmental endothelial locus-1
(Del-1) and endothelial CD47 interacting with monocyte sig-
nal regulatory protein-𝛼 (SIRP-𝛼) [90, 91]. Thus, monocyte-
endothelial interactions seem to be regulated at different
levels and most likely other regulation mechanisms will be
unraveled in the near future.
3.4. Crawling. After firm adhesion, leukocytes spread and
crawl on the endothelial surface to find a suitable spot for
transmigration. This process has first been observed with
monocytes and was called locomotion [92]. Such directional
movement of monocytes preceding transmigration could be
blocked by antibodies against LFA-1 or Mac1 strongly sug-
gesting dependence on 𝛽2-integrins. In the case of patrolling
monocytes, antibodies against LFA-1 but not Mac1 detached
crawling monocytes, an effect that was also observed in mice
lacking CX3CR1 [72]. In unstimulated cremaster venules,
more monocytes (compared to neutrophils) adhered and
crawled for longer distances in an LFA-1-dependent man-
ner. Once stimulated by tumor necrosis factor-𝛼 (TNF-
𝛼), monocytes reduced their crawling distance that now
became Mac1-dependent and more neutrophils crawled in
a strictly Mac-1-dependent fashion [93]. In this study, Mac1
blockage was more efficient in reducing both monocyte
and neutrophil extravasation compared to LFA-1 blockage.
While crawling of monocytes can be both LFA-1-dependent
and Mac1-dependent, neutrophil crawling is strictly Mac1-
dependent [42], thus marking a striking difference between
these leukocyte subsets during extravasation.
3.5. Docking Structures or Transmigratory Cups. During
inflammatory leukocyte recruitment, the activated endothe-
lium supports neutrophils by forming clusters around adher-
ing leukocytes that are enriched in LFA-1/ICAM-1 and
VLA-4/VCAM-1. These structures first appear as ring-like
structures that surround adherent leukocytes and later engulf
leukocytes as docking structures or transmigratory cups
that are enriched in actin and various adaptor molecules
such as cortactin, ezrin, radixin, moesin- (ERM-) proteins,
and filamin, and signaling molecules such as RhoG and
Rac1 [49, 50, 94–100]. Another endothelial adhesion recep-
tor found in docking structures is activated leukocyte cell
adhesion molecule-1 (ALCAM-1) that supports monocyte
recruitment into the central nervous system (CNS) [101].
Docking structures have been observed in vitro with all
leukocytes. In vivo, similar structures, so-called domes, have
been described for neutrophils [102]. Formore details, see the
endothelial part below.
3.6. Diapedesis. In order to cross the endothelial monolayer
between intercellular junctions, the VE-cadherin/catenin
complex needs to be disassembled as it constitutes a physical
barrier for transmigrating leukocytes [47]. Real-time imaging
of transmigration in vitro using VE-cadherin-GFP overex-
pressing HUVEC revealed that monocytes as well as neu-
trophils used preexisting and de novo-formed VE-cadherin
gaps to achieve paracellular transmigration [103]. Interest-
ingly, initial transmigration of monocytes causes downreg-
ulation of VE-cadherin and upregulation of PECAM-1 that
facilitates subsequent monocyte transmigration [104]. Other
molecules of the interendothelial junctions can actually be
exploited as counter-receptors by transmigrating leukocytes
to facilitate transmigration. For example, monocyte LFA-1
can bind to JAM-A and JAM-A deficiency greatly reduces
transmigration ofmonocytes [105, 106]. In the brain, blocking
JAM-A interactions with LFA-1 reduced transmigration of
monocytes and neutrophils and ameliorated the overall
neurological damage after ischemia/reperfusion injury [107].
Expression of JAM-like protein (JAM-L) is upregulated on
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monocytes during inflammation and binds to the endothe-
lial receptor coxsackie and adenovirus receptor (CAR), an
interaction that is regulated in cis by VLA-4 [108, 109]. Other
adhesionmolecules within EC contacts that serve as counter-
receptor during inflammatory monocyte recruitment are
PECAM-1, CD155, and CD99. PECAM-1 and CD99 interact
homophilically, whereas endothelial CD155 interacts with
CD226onmonocytes. Blockade of all thesemolecules that are
part of the lateral border recycling compartment (LBRC, [52])
by antibodies drastically reduced monocyte TEM without
affecting rolling, adhesion, and crawling [110–112]. Inter-
estingly, these molecules act in a sequential manner with
PECAM-1 engagement occurring first followed byCD155 and
then CD99 [112]. Moreover, occludin in the tight junction
controls monocyte transmigration across the blood-brain
barrier in response to methamphetamine in an actin-related
protein-2/3- (Arp2/3-) dependent fashion [113]. Inhibit-
ing Arp2/3 prevented methamphetamine-induced occludin-
internalization and monocyte TEM.
3.7. Postdiapedesis Events. In order to cross the BM and
the pericyte layer, both monocytes and neutrophils exploit
areas of pericyte gaps and low matrix protein expression
within the BM [10, 69]. However, while neutrophils were
capable of enlarging these low matrix protein expression
regions, monocytes showed increased deformability and
rather squeezed through them [69]. NG2+-pericytes also
guide and bind transmigrated monocytes and neutrophils
by chemokine secretion and ICAM-1 expression, respectively
[114]. A commonmechanism for all leukocytes after crossing
the EC layer is the elongation of uropods and a delayed
detachment of the leukocyte from the basal endothelial
surface [68]. This process depended on LFA-1 interaction
with abluminal ICAM-1 that maintained the connection of
the uropod with the endothelium and, on the other hand, on
VLA-3 that mediated movement through the BM. Signaling
required for tail retraction after diapedesis involves RhoA
[115]. Inhibiting RhoA in monocytes renders the cells unable
to complete diapedesis and leads to𝛽2-integrin accumulation
in the unretracted tail. Vice versa, RhoA activation in EC
is also required for efficient monocyte transmigration [116]
which involves ROCK-mediated myosin light chain phos-
phorylation and disruption of VE-cadherin-dependent EC
contacts [117].Monocytes that fully transmigrated express the
surface receptor discoidin domain receptor-1𝛼 (DDR1𝛼) that
can bind collagen and seems to facilitate monocyte migra-
tion within collagen-rich extracellular matrices (ECM) in
inflamed tissues [118]. Interestingly, monocytes can undergo
reverse transmigration when JAM-C-mediated adhesion is
disrupted by antibodies in vivo [119].
4. Mechanisms Exploited by Lymphocytes to
Achieve TEM
T and B lymphocytes (T and B cells) are adaptive immune
cells capable of recognizing and distinguishing antigens lead-
ing to functional specificity and memory. T and B cells arise
from the bonemarrow and populate the peripheral lymphoid
organs (spleen and lymph nodes), where they complete
maturation and become activated in response to specific
antigens presented by antigen presenting cells, including den-
dritic cells (DCs). Trafficking to the lymph nodes occurs via
lymphocyte L-selectin-dependent adhesion to its ligands on
high endothelial venules (HEV), glycan-bearing cell adhesion
molecule-1 (GlyCAM-1), and CD34, followed by integrin-
dependent arrest via LFA-1 and VLA-4. The affinity of these
integrins is rapidly increased by the chemokines CCL19 and
CCL21 that are mainly produced in lymphoid tissues by HEV.
These chemokines then bind to CCR7 expressed in both
na¨ıve T cells and B cells. Upon antigen presentation, na¨ıve
T and B cells become activated and lose L-selectin expression
[120–122]. Activated lymphocytes can either become effector
cells or memory cells. Effector B cells produce antibodies
that contribute to the elimination of extracellular microbes.
Effector T cells can be separated into CD8+ cytotoxic T cells,
which kill virus-infected cells, and subsets of CD4+ T cells
including T helper (Th) cells that help other immune cells
carry out their functions, and T regulatory (Treg) cells that
suppress the functions of effector T lymphocytes. T and B cell
subsets are further divided into well-defined subtypes that
play different roles in health and disease [123]. In this section,
we summarize the different mechanisms exploited by T and
B cells to achieve transendothelial migration. Extravasation
of T cell subsets has been studied in more detail in vitro
and in vivo. B cells also infiltrate sites of inflammation in
several diseases [124–126] but it is assumed that B cells
largely exploitmechanisms similar to those of T cells. Current
studies focusing on B cell extravasation are discussed at the
end of this section.
4.1. Mechanisms of T Cell Extravasation. T lymphocytes
(T cells) are specialized leukocytes that have the ability of
recognizing antigens and participate in the adaptive immune
response. The process of T cell recruitment to sites of
infection or injury is fundamental in the immune response
to exogenous antigens, with implications for responses
to autoantigens that trigger chronic tissue inflammation
when immune tolerance is disrupted in autoimmunity [127].
Within the T cell recruitment cascade, T cell adhesion is
perhaps the best-understood process under flow conditions,
with several in vitro studies involving human CD3+ T
cells and T cell-like cell lines characterizing the molecular
signals regulating chemokine-induced integrin activation
[128]. These in vitro studies using human T cells have
also demonstrated that the behavior of T cells differs from
other leukocytes once contact with the activated vascular
endothelium is established. T cells randomly adhere to the
apical side of the endothelium and locomote on the surface
for some time. This is thought to be required to allow for
enough time to induce the chemokine-chemokine receptor
crosstalk necessary for optimal T cell integrin activation and
subsequent TEM [129]. This contact time also allows the T
cell receptor (TCR) to recognize potential antigens being
presented by vascular EC, a recently explored pathway that
can also lead to TEM [130]. Recent studies on different T cell
subsets expanded the classic paradigm of T cell recruitment
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by identifying novel critical molecules and pathways leading
to T cell extravasation in vivo.These involve common but also
T cell-specific molecules that participate in the different steps
of the T cell recruitment cascade as summarized below.
4.1.1. Rolling. Rolling of T cell subsets has mostly been
characterized using CD4+-T cells, with the understanding
that many findings may also hold true for CD8+-T cells [131,
132]. As in other leukocytes, T cell rolling occurs under shear
conditions by interactions of endothelial selectins with highly
glycosylated T cell-expressed selectin ligands. In contrast to
other leukocytes such as neutrophils and monocytes, which
constitutively express all the glycosyltransferases required for
functional selectin ligand biosynthesis, these are normally
inducible and regulated in T cells [21].Therefore, the ability of
T cells to bind endothelial selectins is acquired in response to
signals that assure the proper glycosylation of selectin ligands.
These signals include specific cytokines, and thus T helper
type 1 (Th1) cells andThelper type 2 (Th2) cells, which require
different cytokines for differentiation and survival [133, 134],
differ in the initial rolling step of the T cell recruitment
cascade due to the differential expression of active selectin
ligands. Th1 cells are major players in immune responses
to intracellular microbes and in tissue damage associated
with autoimmunity and chronic infections.They express high
levels of glycosyltransferases in response to the Th1 cytokine
IL-12 and thus have highly glycosylated selectin ligands for
rolling on the activated endothelium. Th2 cells contribute
to fight against helminth infections and autoimmune atopic
diseases but have a rather low extravasation potential com-
pared to Th1 cells [135–137]. The more recently discovered
Th17 cells participate in the immune response to extracellular
bacteria and fungi and, similarly to Th1 cells, play a role
in organ-specific autoimmunity and chronic inflammation
[138]. Interestingly, both Th1 and Th17 cells share selectin
ligands such as PSGL-1 to roll on the vascular endothelium
via P-selectin [139]. More recent data indicate that these
subsets, in contrast to the Th2 or na¨ıve cells, can also use
the T cell immunoglobulin and mucin domain 1 protein
(TIM-1) as a P-selectin ligand to mediate T cell trafficking
during inflammation and autoimmunity [140]. Similarities
and differences in rolling mechanisms are observed in E-
selectin-ligand/E-selectin mediated interactions among T
cell subsets, with Th17 cells being more dependent on E-
selectin-mediated interactions than Th1 cells [139]. Besides
PSGL-1 which functions similarly in Th1 and Th17 cells as
a ligand for both E-selectin and P-selectin, other E-selectin
ligands have been identified in Th1 cells that are functional
only in cooperation with PSGL-1, and these include CD44
[141] and CD43 [142, 143]. Further research will determine
whether these can also function in Th17 cells in a subset
specific manner.
4.1.2. Adhesion. The emerging novel roles for different T
cell subsets in acute and chronic inflammatory processes
and the differential expression of chemokine receptors in
different T cell subsets have recently been recognized as being
critical for integrin-mediated adhesion in response to specific
chemokine-chemokine receptor signaling [144].The integrin
associated protein (CD47) has been shown to regulate adhe-
sive functions of the 𝛽2-integrins LFA-1 and VLA-4 in T
cells in vitro. This was proven to be a critical mechanism
regulating T cell adhesion to the cremaster microvasculature
in vivo in studies involving competitive recruitment of CD47
wild type and CD47-deficient Th1 cells [145]. The integrin
coactivator Kindlin-3 has also recently been shown to rein-
force T cell integrin activation and adhesion. Interestingly,
this mechanism is specific for T cell adhesion but did not
play a role in T cell diapedesis [146]. Studies using mouse
Th1 andTh17 cells generated in vitro have also demonstrated
that these cells express a different repertoire of chemokine
receptors. Depending on the chemokine ligand exposed,
these two subsets adhered to immobilized ICAM-1 only in
the presence of SDF1𝛼 and CCL20, respectively, under shear
flow conditions in vitro. Other studies using human T cells
and HUVEC also demonstrated that CCL20 mediates Th17
adhesion to EC [147]. These studies nicely correlate with in
vivo studies showing a role for CCR6, the receptor of CCL20,
in specific CCR6+-Th17 cell recruitment to the gut [148], to
the central nervous system [149], and to the skin [139]. These
adhesion mechanisms are therefore chemokine/chemokine
receptor-specific. They may also be tissue specific, as Th17
cells in liver endothelium utilize vascular adhesion protein-
1 (VAP-1) and the chemokine receptor CXCR3 in addition to
CCR6 to mediate adhesion via 𝛽1 and 𝛽2 integrins [150].
4.1.3. Diapedesis. T cell TEM follows rolling and adhesion
and ultimately leads to T cell infiltration into inflamed
sites. Compared to other leukocytes such as neutrophils, the
percentage of T cells that undergo TEM in in vitro assays
under flow conditions is much smaller, and it normally
requires additional chemokines such as SDF1𝛼 in order to
facilitate T cell arrest and TEM. Similarities with other
leukocytes include ICAM-1-mediated signaling upon T cell
adhesion, and VE-cadherin gaps at the site of junctional
transmigration [151–153]. Recent work has demonstrated that
T cells can trigger the dissociation of the endothelial receptor
phosphatase VE-PTP from VE-cadherin as a mechanism
leading to VE-cadherin phosphorylation and gap formation
to facilitate transmigration [154]. Endothelial CD47 can also
promote VE-cadherin phosphorylation and participate in T
cell transmigration in vitro. Interestingly, CD47 expressed
on T cells is also required for T cell TEM in vitro and for
T cell recruitment at sites of dermal skin inflammation in
vivo [155]. In vitro, VAP-1 can mediate TEM of T cells across
liver EC [156]. More recent studies have demonstrated that
VAP-1 together with the common lymphatic endothelial and
vascular endothelial receptor (CLEVER-1) and ICAM-1 can
specifically regulate TEMof Treg cells [157]. VAP-1, CLEVER-
1, and ICAM-1 are highly expressed at sites of leukocyte
recruitment to the inflamed liver suggesting that they also
regulate T cell transmigration into the liver in vivo. From
all these studies it is clear that chemokines presented by
the endothelium are critical for integrin-dependent adhesion
and TEM of effector and memory T cells in vitro. This has
significant implications in vivo, where chemokine gradients
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are present in the context of infection or injury leading to T
cell transmigration. A novel alternativemechanismdescribed
for T cell transmigration is the ability of effector T cells to
access not only extracellularly deposited chemokines, but also
intraendothelial chemokines such as CCL2 stored in vesicles
inside the EC to achieve transmigration [158].
As different T cell subsets were identified as principal
players in chronic inflammation, a role of the vascular
endotheliumhas been considered as critical for themigratory
patterns acquired by antigen-experienced effector T cells
that migrate to sites of chronic inflammation. Whether
these pathways are T cell subset specific or organ/vascular
bed/disease-specific remains to be investigated [164]. Given
that EC express major histocompatibility complex molecules
(MHC) I and II and therefore can function as antigen pre-
senting cells for both CD4+- and CD8+-T cells, it is recently
being recognized that, at the time of contact and antigen
presentation, EC can imprint restricted, specific trafficking
molecules in T cells. These are thought to be acquired in the
organ where the T cells were generated [165], or at the site
of infection or inflammation, where these antigenic signals
are thought to contribute to the recruitment of these T cell
subsets [166, 167]. Thus, the classic paradigm of chemokine-
induced T cell arrest and TEM is now being challenged with
alternative ways that T cells use to achieve TEM in different
inflammatory contexts. In vitro, both effector and memory
CD4+- and CD8+-T cells dynamically probe the endothelium
by extending actin-rich invadosome/podosome like protru-
sions (ILPs) [168], thought to actively participate in TEM by
distorting the actin filaments and breaching the endothelial
barrier [9]. In vivo mouse studies have shown that antigen
specific CD4+-effector T cells use cognate antigen driven
signals presented byMHC-II for entry into pancreatic islets in
autoimmune diabetes [169, 170]. Apical presentation of cog-
nate antigenic peptides byMHC-I and perivascular dendritic
cells are thought to increase integrin adhesiveness and TEM
of CD8+-T cells in vascular beds deficient in adhesive and
chemotactic activities such as the pancreatic islets in diabetes
[167] and vascularized transplants [171]. In vitro studies
under flow conditions using human effector and memory
CD4+-T cells have contributed to gain further insight into
the mechanisms taking place in TEM mediated by antigen
presentation and TCR signals versus classic chemokine-
induced TEM not involving antigenic signals. These studies
have demonstrated that T cells can rapidly transmigrate in
response to both chemokines and TCR-activating antigenic
signals, but these two mechanisms differ in some of the
molecular pathways regulating TEM: TCR stimulated TEM
was highly dependent on fractalkine (CX3CL1), PECAM-1,
CD99, nectin-2, poliovirus receptor (CD155), and ICAM-1,
whereas chemokine-stimulated TEM involved ICAM-1 and
JAM-Abut not any of the othermolecules [172]. Furthermore,
both of these TEM pathways triggered the activation of the
protein ZAP-70 in the transmigrating T cell but differ in the
signaling downstream of ZAP-70. Vav-1, Rac-1, and myosin
2A activation occurred only in the T cells that have been
in contact with vascular EC in an antigen-TCR dependent
way [173]. Phenotypically, this signaling resulted in different
T cell cytoskeleton reorganization during transmigration,
with the T cell microtubule organizing center (MTOC) being
organized in the contact region between the T cell and
the EC. Dynein-driven transport of granzyme-containing
granules to the contact region between the T cell and the
EC was identified as the mechanism regulating the T cell
cytoskeleton reorganization during TEM [174]. Thus, these
specific molecular signals observed in TCR-driven T cell
transmigration closely resemble immune synapse formation
and seem to be a novel process that T cells utilize to achieve
successful TEM.
Taken together, T cells are uniquely specialized to
respond to antigens, proliferate, and differentiate into subsets
that acquire migratory phenotypes that allow them to traffic
to sites of inflammation previously accessed by neutrophils
and monocytes. T cells share some of these recruitment
mechanisms with other leukocytes and trigger similar sig-
nals on the vascular endothelium to achieve TEM. The
specialized T cell response to different antigens and the
cytokinemilieu results in distinct expression of active selectin
ligands and a different repertoire of chemokine receptors
involved in rolling and arrest on the vascular endothelium.
Once adhered to the endothelium, they can use classic TEM
routes and novel antigen-dependent routes. Understanding
the mechanisms that regulate the recruitment of effector
T cells in different inflammatory settings will shed new
light on potential ways these pathways can be exploited for
immunotherapeutic purposes.
4.2. Mechanisms of B Cell Extravasation. As mentioned
above, B cells utilize in general the same basic mechanisms
as na¨ıve T cells to home to secondary lymphoid organs.
How activated B cell subsets migrate into specific tissues
during inflammation has not been explored in such detail
as for T cell subsets, for which each step of the recruitment
cascade has been analyzed in vitro and in vivo. However, some
studies have identified some differences in inflammatory B
cell extravasation as compared to T cells that will be discussed
here. Many mature B cells, named plasma cells, migrate from
the lymph nodes to the bone marrow, where they secrete
IgG antibodies for long periods of time that are distributed
through the body via the blood stream. This B cell subset
expresses VLA-4 and CXCR4, which bind to VCAM-1 and
CXCL12, respectively, expressed in bone marrow sinusoidal
endothelial cells. In contrast, mature B cells that produce
IgA antibodies, express 𝛼4𝛽7, CCR9, and CCR10 which bind
to MadCAM-1, CCL25, and CCL28, respectively, expressed
in mucosal endothelial cells to migrate to mucosal tissues
such as the gut [175, 176]. These molecules are also thought
to mediate IgG and IgA-producing B cell recruitment to
sites of chronic inflammation in the synovium [124], the
brain [125], and the vessel wall [126]. Moreover, CXCL12
was able to stimulate diapedesis of human B cells across
human brain microvascular endothelial cells under flow
conditions, and this was blocked by CXCR4 function block-
ing antibodies [159]. Recently, ADAM28, which is highly
expressed in B cells but not in T cells, has been shown to
bind to VLA-4 and to increase VLA-4-dependent adhesion
of the murine B lymphoma cell line L1-2 to VCAM-1 and
subsequent transendothelial migration suggesting that this
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metalloprotease affects the efficiency of B cell extravasation
[177]. Interactions of ephrin-A4 with its endothelial receptor
EphA2 have also been shown to regulate normal as well as
leukemic B cell transendothelial migration [178]. B cells are
also present within chronically inflamed liver tissue. Using in
vitro flow adhesion assays and hepatic sinusoidal endothelial
cells, human blood-derived B cells were captured via VCAM-
1 without requiring a previous rolling phase and remained
static before achieving transendothelial migration mediated
by ICAM-1, VAP-1, and the chemokine receptors CXCR3 and
CXCR4. This mechanism represents a prominent difference
in B cell extravasation, since T cells displayed vigorous
crawling before transmigration in the same system [160].
Others have observed so-called “intraendothelial canalicu-
lar” structures that are especially exploited by B cells to cross
the endothelium during homing and inflammation [179].
Whether these structures can also be observed during the
extravasation of other leukocyte types needs to be analyzed
in the future.
5. The Dynamics of Leukocyte Diapedesis from
an Endothelial Point of View
Under quiescent conditions, the endothelium expresses low
levels of adhesion molecules, allowing limited immune
surveillance. However, upon encounter of an infection or
tissue damage, surveilling monocytes and neutrophils are
triggered to release inflammatory cytokines, such as TNF-
𝛼 and IL1𝛽. The importance of this has been recently
underscored by the group of Dr. Nourshargh [180]. They
showed in an elegant in vivo model that neutrophils locally
secretedTNF-𝛼which immediately acted on the endothelium
and thereby assisted other neutrophils in transmigration. For
longer periods of inflammation, EC respond to inflammatory
mediators by massive upregulation of adhesion receptors,
such as P-selectin, E-selectin, ICAM-1, andVCAM-1,whereas
ICAM-2 was found to be decreased [181, 182].These adhesion
molecules attract circulating immune cells to adhere to and
transmigrate through the endothelial monolayer (Figure 1).
Moreover, inflammatory cytokines induce presentation of
chemoattractants on the EC surface, such as CXCL4/5 and
IL-8 [14]. During rolling, G-protein-coupled receptors on
the leukocytes encounter such chemokines presented by the
EC and signal to induce a conformational change of the
leukocyte integrins LFA-1 (𝛼L𝛽2) and VLA-4 (𝛼4𝛽1) into a
high affinity state enabling these integrins to interact with
their endothelial ligands ICAM-1 and VCAM-1, respectively
[13, 183]. As a consequence, firm adhesion, crawling, and
finally diapedesis occur via interendothelial junctions or
through the EC body [184]. Although these processes are
believed to occur for any type of leukocyte that crosses
the endothelium, some endothelial signals are specifically
induced by certain leukocyte subsets that we will highlight
in this chapter.
5.1. Adhesion Molecule Upregulation. The inflammatory
cytokine TNF-𝛼 stimulates EC by binding to its recep-
tor TNFR1 (CD120a) [185, 186]. This binding induces the
association of the cytoplasmic adaptor protein TRADD
(TNFR1-Associated Death Domain protein) to the intracel-
lular domain of TNFR1. Subsequently, TRADD binds to
downstream effectors such as the serine/threonine kinase
RIP1 (Receptor Interacting Protein 1), as well as the E3-
ubiquitin ligase TRAF2 (TNFR-associated Factor 2). This
association in turn triggers a kinase signaling cascade leading
to the activation of the mitogen-activated protein kinases
(MAPKs) p38, JNK, and ERK [187]. These kinases are able to
activate transcription factors, such as activator protein-1 (AP-
1). In addition, TRAF2 and RIP1 induce the activation of the
transcription factor NF-𝜅B. Under quiescent conditions, NF-
𝜅B is retained in the cytosol by inhibitor of 𝜅B (I𝜅B𝛼). Upon
activation of the I𝜅B𝛼 kinase (IKK) complex by TRAF2 and
RIP1, I𝜅B𝛼 is phosphorylated, which leads to its degradation
and the subsequent nuclear translocation of NF-𝜅B [188].
The promoters of the adhesion molecules E-selectin,
VCAM-1, and ICAM-1 contain several NF-𝜅B-binding sites,
and NF-𝜅B has been shown to be the primary regulator of
TNF-𝛼-induced adhesion molecule expression in EC [189–
194]. Although the promoters of E-selectin, VCAM-1, and
ICAM-1 also contain AP-1-binding motifs, these sites have
varying contributions to TNF-𝛼-induced upregulation of
these adhesion molecules [192, 193, 195, 196]. In addition,
other transcription factors such as Interferon Regulatory
Factor-1 (IRF-1), Specificity protein 1 (Sp1), and GATA are
also known to become activated via poorly characterized sig-
naling pathways and contribute to TNF-𝛼-induced adhesion
molecule upregulation in EC [191, 197–199].
5.2. Signaling by CAMs. The integrin expression patterns
differ per leukocyte type. For example, neutrophils pri-
marily express Mac1 and LFA-1 and hardly any VLA-4,
whereas monocytes and also T-lymphocytes and dendritic
cells express all three integrins, albeit at different levels [200].
This already indicates that different leukocyte types through
their integrin repertoire can cluster different ligands on the
endothelium resulting in distinctive intracellular signals in
the endothelium that differ per leukocyte type. For example,
Th17-lymphocytes showed increased adhesion to E-selectin
compared toTh1-lymphocytes, most likely because of a better
integrin activation on these cells through the CCL20-CCR6
axis [139].
ICAM-1 and VCAM-1 are members of the immunoglob-
ulin (Ig) superfamily of adhesion molecules, whose extra-
cellular domains are characterized by the presence of five
and six Ig-like domains, respectively. Compared to their
ectodomains, ICAM-1 and VCAM-1 have relatively small
carboxyl- (C-) terminal intracellular domains of only 28
and 19 amino acids, respectively. Although the C-terminal
domains do not contain any apparent signaling motifs,
the intracellular domain of ICAM-1 has been shown to be
required for efficient leukocyte TEM [201, 202]. Moreover,
ICAM-1 engagement by LFA-1/Mac1 has been linked to F-
actin reorganization and to the initiation of signaling events
within EC [203]. Several studies have shown that leukocyte
adhesion and clustering of ICAM-1 induced an increase in
intracellular Ca2+ levels [204, 205] leading to activation of
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the tyrosine kinase Src by protein kinase C (PKC). In
turn, Src induced tyrosine phosphorylation of focal adhesion
proteins such as paxillin, cortactin, and FAK [204, 206,
207]. ICAM-1 clustering led to the activation of the small
RhoGTPase RhoAwhich stimulated the formation of F-actin
stress fibers and increased endothelial monolayer perme-
ability [204, 208–210] (Figure 2). Moreover, RhoA activity
was also demonstrated to be required for efficient ICAM-
1 recruitment around adherent monocytes [210] suggesting
an upstream role for RhoA within the ICAM-1-induced
signaling cascade. Recently, it was shown that ICAM-1 clus-
tering induced tyrosine phosphorylation of VE-cadherin in
a Src- and Pyk2-dependent manner, which coincided with
increased endothelial permeability [203, 211, 212]. Martinelli
and colleagues showed that ICAM-1 clustering induced the
phosphorylation of eNOS on S1177 and this was regulated
by Src kinase, as well as RhoA, calcium, CaMKK, and
AMP kinase, but not PI3 kinase. They additionally showed
that this pathway controlled the phosphorylation of VE-
cadherin and lymphocyte trafficking [203]. In contrast to
ICAM-1, only a few studies have reported signaling events
induced upon engagement and clustering of VCAM-1. The
leukocyte integrin VLA-4, expressed on monocytes and
lymphocytes, showed strong binding preference for VCAM-
1 [213]. Clustering of VCAM-1 was shown to promote
activation of Rac1 leading to the production of reactive
oxygen species (ROS) [214–216]. VCAM-1-dependent ROS
production was demonstrated to regulate the activation of
matrix metalloproteases, which may contribute to the local
breakdown of the endothelial adherens junctions [217]. In
addition, VCAM-1 clustering was shown to regulate lym-
phocyte TEM by activation of the kinase PKC𝛼 and the
tyrosine phosphatase PTP1B in a ROS-dependent manner
[218, 219].
In addition to the classical adhesion molecules on the
endothelium (e.g., ICAM-1/2 and VCAM-1), several other
molecules are known to play an important role in leukocyte
traffic. Several of them belong to ectoenzymes, which are cell
surface molecules having catalytically active sites outside the
cell. For example, the adhesion molecule Vascular Adhesion
Molecule-1 (VAP-1) with amine oxidase enzymatic activity
was discovered to be present at the endothelial surface and
controls the traffic of lymphocytes [220–222], monocytes
[161], and neutrophils [162, 163]. However, if these ectoen-
zymes transmit intracellular signals into the endothelium that
remodel the actin cytoskeleton during leukocyte TEM is not
known.
The transmembrane protein CD47 is also an impor-
tant mediator of leukocyte trafficking [145, 155]. CD47 is
expressed onmany if not all leukocyte types as well as EC and
interacts with SIRP𝛾 that is expressed on lymphocytes [223].
The same group showed that CD47 can phosphorylate VE-
cadherin and in this way mediate lymphocyte TEM, again in
a Src- andPyk2-dependentmanner [155]. Interestingly, cross-
linking of CD47 with antibodies led to formation of stress
fibers, similar to what has been observed when cross-linking
ICAM-1 [209, 210, 224]. Clearly, changes in the endothelial
actin cytoskeleton induced by leukocyte binding control
efficient leukocyte TEM.
Tetraspanins form microdomains in the plasma mem-
brane and are involved in intercellular adhesion and migra-
tion. For lymphocyte and monocyte TEM, it has been
reported that the tetraspanins CD9, CD81, and CD151 dis-
tribute to the contact site with transmigrating leukocytes
and associate laterally with both ICAM-1 and VCAM-1 [225,
226]. They control the adhesive capacity of the adhesion
molecules and thereby control leukocyte binding strength to
the endothelium. In addition, Barreiro and coworkers found
that tetraspanins can form so-called endothelial adhesive
platforms (EAPs) to which leukocytes can bind [95]. These
platforms can function as signaling hubs in the plasma
membrane and may include lipid rafts as well. Interestingly,
ICAM-1 andVCAM-1 can both be present in these platforms,
independent of the presence of its receptor.
A summary of the above-described signaling pathways
downstream of clustered ICAM-1 and VCAM-1 is shown in
Figure 2, where we have color-coded the endothelial proteins
that are activated by specific leukocyte subsets.
5.3. CAM Linkage to the F-Actin Cytoskeleton. To support
proper adhesion under physiological flow conditions, ICAM-
1 and VCAM-1 need to be intracellularly anchored to the
cytoskeleton. In the past two decades, several actin adapter
proteins have been reported to interact with the intracellular
domains of VCAM-1 and ICAM-1. These adapter proteins
link these molecules to the F-actin cytoskeleton (Figure 2).
The adapter proteins ezrin and moesin from the ERM-family
were found to interact with VCAM-1 in a direct manner.
Moreover, they colocalized with VCAM-1 around adherent
lymphoblasts [94]. Their ability to bind both phospholipids
and F-actin allows ERM proteins to organize adhesion
molecules into specialized membrane domains [227]. In
addition to VCAM-1, ERM proteins were also reported to
interact with ICAM-1 in a PIP
2
-dependent manner and
colocalized with ICAM-1 in microvilli-like structures [94,
210, 228, 229]. However, unlike the binding to VCAM-1, the
interaction of ezrin and moesin with ICAM-1 was reported
to be indirect [230]. In addition to ERM proteins, the F-actin
bundling proteins 𝛼-actinin-1 and -4 were also demonstrated
to interact with the ICAM-1 C-terminus through a cluster
of ICAM-1-C-terminal positively charged amino acids [231,
232]. Interestingly, this same cluster of amino acids was
shown to mediate the interaction of ICAM-1 with ezrin [229]
suggesting that 𝛼-actinin and ERM proteins may compete
for binding to ICAM-1. This also indicates the existence of
different ICAM-1/actin complexes upon leukocyte-mediated
clustering (Figure 2).
The cortical actin-binding protein cortactin was initially
shown to become tyrosine phosphorylated upon ICAM-
1 clustering [206] and this tyrosine phosphorylation was
required for efficient neutrophil TEM [100]. Cortactin is
thought to stabilize branched actin networks through inter-
action with the Arp2/3 complex [233]. It also associated with
ICAM-1 upon clustering [234] and was required for ICAM-
1 and F-actin recruitment to ring-like structures around
adherent leukocytes [99]. Recently, it was shown that cor-
tactin is also required for ICAM-1 clustering around adherent
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Figure 2: Endothelial signaling pathways induced upon clustering of ICAM-1 and VCAM-1 leading to the formation of endothelial F-actin-
rich apical cup structures and the dissociation of endothelial adherens junctions. Endothelial signals that are induced by specific leukocyte
types are color-coded: neutrophils in green, monocytes in red, T cells in blue, and B cells in purple. In case signaling proteins are identified
by studies using different leukocyte types, the background color of the protein name is adapted to the leukocyte type used. In case specific
signaling is studied in the absence of leukocytes the color is black. Short stripes indicate glycosylation. Questionmark indicates that GlyCAM-
1, as a soluble protein, may reassociate to the endothelial membrane.
neutrophils and for efficient neutrophil extravasation in vivo,
thus highlighting the physiological relevance of the ICAM-1-
cortactin interaction [49].
Finally, Kanters and colleagues showed that the F-actin
cross-linker protein filamin B interacts with the ICAM-1
C-terminus in a direct manner [235]. Similar to cortactin,
filamin B was required for ICAM-1 recruitment to a ring
around adherent neutrophils and for neutrophil TEM under
physiological flow conditions. In amore recent publication, it
was shown that also filamin A interacts with the intracellular
tail of ICAM-1 [236]. It has therefore been proposed that
these adapter proteins connect ICAM-1 to downstream sig-
naling partners [237, 238]. Silencing of filamin B expression
impaired ICAM-1 clustering and leukocyte TEMunder phys-
iological flow conditions and since filamin A was still present
in filamin B-silenced EC, this suggests that the filamins are
not functionally redundant.
Indeed, although filamins A and B share 70% amino
acid sequence identity, different effects on ICAM-1 function
were observed when either filamin A or filamin B was
silenced. Using fluorescence recovery after photobleaching
(FRAP) technology, it became clear that silencing of filamin B
expression increased the immobile fraction of ICAM-1 in the
plasma membrane [235]. In contrast, in EC lacking filamin
A, the immobile fraction of ICAM-1 was reduced [239].
Additionally, the clustering-induced ICAM-1-actin associa-
tionwas impaired in filaminA-silenced EC, but not in filamin
B-silenced EC (personal observation, JDvB). The effects of
filamin A deficiency on ICAM-1 function are similar to those
of inhibition of F-actin polymerization.Moreover, deletion of
the intracellular domain of ICAM-1 decreased the immobile
fraction of ICAM-1 [239]. In addition, filamin A, but not
filamin B, also mediated the interaction of ICAM-1 with the
lipid raft marker and main constituent of caveolae, caveolin-1
[235]. Since ICAM-1 is recruited to caveolae and caveolin-1
during transcellular lymphocyte TEM [240], filamin A may
have a specific role in regulating the transcellular pathway
of diapedesis. These findings therefore reveal important roles
for the different filamins in controlling ICAM-1 dynamics by
regulating the connection with the F-actin cytoskeleton and
specific membrane domains.
Recently, it became clear that there is a hierarchy between
these actin-binding proteins to bind to ICAM-1 upon clus-
tering. Schaefer and colleagues showed that when ICAM-
1 is clustered, 𝛼-actinin is the first protein to be recruited
to ICAM-1, followed by cortactin and lastly filamin [241].
The recruitment of different adapter proteins to ICAM-1 may
result in the composition of a different actin network. For
example, 𝛼-actinin cross-links actin filaments into actin bun-
dles whereas cortactin cross-links actin into a meshwork and
filamin into a “gel-like” structure [233, 237]. The initiation of
these different actin networks may generate forces that drive
local protrusive activity, that is, docking structures, or create
a surface for leukocytes to crawl on. In fact, they showed
that the local stiffness of the EC was indeed dependent on
𝛼-actinin. Depleting 𝛼-actinin resulted in reduced ability
of the neutrophils to spread and transmigrate [241]. The
group of Dr. Carman showed recently that the cytoskeletal
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morphology and as a consequence the local EC stiffness of
different vascular beds determined the preferred route for
T-lymphocytes to cross the endothelium [9]. In particular,
high barrier functionwas associatedwith transcellularmigra-
tion, whereas artificial opening of the junctions resulted in
more paracellular migration.They previously showed that T-
lymphocytes use invadopodia-like protrusions to probe the
endothelial surface, possibly to initiate transcellular migra-
tion [242]. It is tempting to speculate that the rate of clustering
of adhesion molecules like ICAM-1 or VCAM-1 determines
the stiffness of the underlying endothelial surface and that
this may be the trigger for, at least, T-lymphocytes to cross.
Whether other leukocyte types, for example, neutrophils or
monocytes, use the same mechanism to probe the surface is
not known.
A recent study by the Woodfin group showed that, next
to ICAM-1 and VCAM-1, ICAM-2 plays an important role in
immune cell traffic in vivo as described above [45]. Whether
clustering of ICAM-2 recruits actin adapter proteins and
induces similar signals is not clear [202]. However, the role
of ICAM-2 seems to be more restricted to certain organs. For
example, endothelial ICAM-2 is required for themigration of
T-cells across the blood-brain barrier [243, 244].
5.4. Endothelial Docking Structure Formation. Using confo-
cal microscopy, Barreiro and coworkers showed that both
ICAM-1 andVCAM-1were recruited to actin-richmembrane
protrusions that surround adherent T-lymphoblasts in cup-
like structures that were termed endothelial docking struc-
tures [94]. Two subsequent studies by Carman and coworkers
demonstrated that the formation of these structures was
dependent on F-actin polymerization and correlated strongly
with transmigrating leukocytes [96, 97]. They suggested
that these structures may function to facilitate and guide
leukocyte TEM by forming a cup-like traction structure
that is aligned parallel to the direction of transmigration.
Interestingly, they showed that the transmigratory cups
were essentially equal between monocytes, neutrophils, and
lymphocytes. Thus, the cups did not discriminate between
the leukocyte types suggesting that these endothelial cups
represent a more global mechanism for leukocyte extravasa-
tion. In contrast to what Barreiro and coworkers proposed,
that is, that the docking structures are required for leukocyte
adhesion, Carman and colleagues showed that the cups
were highly associated with leukocytes that transmigrated.
Disruption of the cups did not alter the capacity of leukocytes
to adhere to the endothelium, even under flow conditions.
Interestingly, the formation of the cups depended on the
intracellular tail of ICAM-1 [98]. In line with the notion
that cups are not involved in adhesion, several reports have
shown that the intracellular tail of ICAM-1 is needed for
proper diapedesis but not for firm adhesion [201, 202, 229].
In addition to the in vitro observations, numerous studies
have also described the formation of endothelial docking
structures in vivo [102, 245–249]. Thus, although definite
proof is still lacking, the formation of docking structures
shows a strong correlation with the diapedesis step.
The initial formation of endothelial docking structures is
dependent on the activity of the small GTPase RhoG [238].
RhoG colocalized with ICAM-1 upon ICAM-1 clustering
and got activated. Moreover, depletion of SGEF, a GEF
for RhoG, or RhoG significantly reduced the formation of
docking structures and neutrophil TEM. Using a murine
model to study the formation of atherosclerosis, it became
clear that SGEF is most likely involved in the recruitment
of monocytes to the site of injury since SGEF-deficient
animals showed a significant reduction of plaques compared
to control animals [250].Thiswork highlights the importance
of docking structures in the development of inflammation-
based diseases such as atherosclerosis.
Interestingly, Doulet and colleagues showed that the
signaling molecules that are normally responsible for the
induction of the apical cup structures can be used by bacteria
(e.g.,Neisseria meningitides) to enter EC [251].These bacteria
titrated the actin adapter protein ezrin and moesin away
from sites where leukocytes interacted on the endothelium
and thereby prevented the formation of cup structures and
leukocyte diapedesis. This study shows the potential clinical
relevance of cup structures in leukocyte TEM during inflam-
mation. How these pathogens manage to cross the vessel wall
and enter host cells can tell us a lot on the basic principles of
the signaling mechanisms during leukocyte TEM.
6. Conclusions
The initial multistep paradigm of leukocyte extravasation
largely describes adhesion and diapedesis from a leukocyte
point of view and regarded the endothelium merely as just a
passive substrate for leukocyte adhesion. However, it is now
well appreciated that the endothelium is also an active partic-
ipant in this process. Clustering of adhesion molecules, such
as ICAM-1 and VCAM-1, has been demonstrated to induce
signaling leading to significant changes in EC morphology
allowing for leukocyte passage. In addition, endothelial cup
structures are formed that may capture and guide leukocytes
to transmigrate across the endothelium. Thus, the essential
role of endothelial adhesion receptors and actin-binding
proteins in mediating leukocyte TEMmakes them promising
candidates for a targeted regulation of leukocyte extravasa-
tion. On the other hand, several mechanisms in leukocytes
have been identified that activate, for example, integrins for
proper interactions with EC and actin dynamics causing
the required morphological changes during TEM. Several
of such mechanisms have been identified in all leukocyte
subsets while others seem to be specific for a given subset.
However, whether they are really specific or have just not
yet been investigated in other subsets remains to be seen
for most of the described mechanisms. It is important to
keep in mind that all leukocyte types, besides their potential
for tissue destruction, fulfill beneficial functions during
many pathophysiological conditions so that pharmacological
targeting of leukocyte recruitment will most likely always
cause beneficial and detrimental effects. Thus, a lot of work
remains to be done until we can fully appreciatewhether there
are truly uniquemechanisms exploited by different leukocyte
subsets duringTEM that could be targeted pharmacologically
in certain pathological conditions that would benefit from
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interference with the recruitment of only one given leukocyte
type without affecting others.
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